BURLINGTON, Mass., Sept. 29, 2014 /PRNewswire/ -- Decision Resources Group finds that one month post-launch, the majority of surveyed gastroenterologists are aware and familiar with Entyvio as a new therapy for the treatment of moderate to severe ulcerative colitis (UC) and Crohn's disease (CD). According to surveyed gastroenterologists, the most commonly cited advantage of Entyvio compared with other currently available biologic treatments includes its different mechanism of action. One month post-launch, less than 20 percent of surveyed gastroenterologists report prescribing Entyvio to their UC and/or CD patients.
Other key findings from the report entitled LaunchTrends: Entyvio (vedolizumab) Wave 1 (U.S.):
- Opportunities for emerging therapies: Less than half of surveyed gastroenterologists are satisfied with the currently available products for moderate to severe UC and CD, and most agree that there is a need for alternate therapies.
- Anticipated use of Entyvio: Although the risk of progressive multifocal leukoencephalopathy (PML) associated with Entyvio is a concern for most surveyed gastroenterologists, the majority of respondents anticipate prescribing the agent to their UC and CD patients within a year.
- Potential candidates for Entyvio: According to surveyed gastroenterologists, TNF-refractory UC and CD patients are the ideal candidates for Entyvio. Janssen Biotech's Remicade and AbbVie's Humira are likely to remain first-line biologics for moderate to severe UC and CD patients.
Comments from Decision Resources Group Analyst Adi Reske, Ph.D.:
- "The majority of surveyed U.S. gastroenterologists are excited about Takeda's Entyvio, and welcome the agent with a different mechanism of action. Within the next year, we anticipate an increase in Entyvio's use, primarily among UC and CD TNF-refractory patients. Until long-term safety data are available, PML will remain a concern among some gastroenterologists, constraining Entyvio use as a first-line biologic."
- "High opportunity exists for emerging therapies in the inflammatory bowel disease market. Improved efficacy in the acute and maintenance setting, long-term safety and more convenient dosing formulations are the highly desired attributes for products in development for UC and CD."
About Decision Resources Group
Decision Resources Group offers best-in-class, high-value information and insights on critical issues within the healthcare industry. Clients rely on this analysis and data to make informed decisions. Find out more at www.DecisionResourcesGroup.com.
All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.
For more information, contact:
Decision Resources Group
SOURCE Decision Resources Group